SUBSCRIBERS

Fresh off one deal, Allergan CEO Saunders sets his sights on more

Published Tue, Jul 28, 2015 · 09:50 PM

New York

ALLERGAN plc CEO Brent Saunders is ready to put the US$36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.

The readiness for a new transaction just after the Teva deal was announced on Monday represents what Mr Saunders calls a strategy to remain nimble and open to opportunity as the healthcare sector remakes itself.

He has already shown a penchant for quick deal-making. Just last year, he helped orchestrate the US$25 billion sale of Fores…

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes

Consumer & Healthcare

Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom
Swiss watch exports plunge as China and Hong Kong demand dries up
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Billionaires selling cheap stuff get richer from inflation pain
Amazon to push cashierless shopping tech into more third-party stores, while backing off itself
Japan’s Uniqlo opens Rome store as part of European expansion

Purchase this article

Companies & Markets

Fresh off one deal, Allergan CEO Saunders sets his sights on more

Consumer & Healthcare

Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom

Swiss watch exports plunge as China and Hong Kong demand dries up

Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO

Billionaires selling cheap stuff get richer from inflation pain

Amazon to push cashierless shopping tech into more third-party stores, while backing off itself

Japan’s Uniqlo opens Rome store as part of European expansion

SUPPORT SOUTH-EAST ASIA'S LEADING FINANCIAL DAILY

SECTIONS

LIFESTYLE

Follow BT